The following trials provide information to treat various types of respiratory and inflammatory diseases, both for ongoing and completed clinical trials. For more information on both of these therapy areas please click here.
- collapse A randomised, parallel-group, open-label, multicentre, 3-month phase IV, efficacy and tolerability study of budesonide/formoterol (Symbicort® Turbuhaler® 160/4.5μg/inhalation, 2 inhalations twice daily) added to tiotropium (SpirivaTM 18 μg/inhalation, 1 inhalation once daily) compared with tiotropium (SpirivaTM18 μg/inhalation, 1 inhalation once daily) alone in severe chronic obstructive pulmonary disease (COPD) patients
- collapse A phase 2, multicenter, open-label, dose-escalation study to evaluate the safety and tolerability of intravenous dose of MEDI-546, a human monoclonal antibody directed against type I interferon receptor (IFNAR), in Japanese subjects with active systemic lupus erythematosus (SLE)
- collapse A 26 Week, Randomized, Double-blind, Parallel-group, Active Controlled, Multicenter, Multinational Safety Study Evaluating the Risk of Serious Asthma-related Events During Treatment With Symbicort®, a Fixed Combination of Inhaled Corticosteroid (ICS) (Budesonide) and a Long Acting β2-agonist (LABA) (Formoterol) as Compared to Treatment With ICS (Budesonide) Alone in Adult and Adolescent (≥12 Years of Age) Patients With Asthma
- collapse A Pharmacoepidemiological study in patients who use Symbicort Turbuhaler as maintenance and reliever therapy capturing over-use and under-use via the General Practice Research Database.
- collapse A randomised single centre phase I study to investigate the safety, tolerability and pharmacokinetics of oral multiple ascending daily doses of AZD1236 tablet by a single-blind, placebo-controlled, and single dose relative bioavailability of the oral suspension and oral tablet formulations by an open cross-over in healthy Japanese men
- collapse A phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled AZD5423 after Administration of Single and Multiple Ascending Doses in Healthy Male Japanese Subjects
- collapse Study to Assess the Pharmacokinetics of Pioglitazone in Healthy Subjects when Administered Alone and in Combination with Fostamatinib 100 mg Twice Daily
- collapse Effects of administration of fostamatinib on blood concentrations of an oral contraceptive in healthy female subjects.
- collapse An Open-Label, Single Centre Study to Assess the Pharmacokinetics and Pharmacodynamics of Warfarin when Co-Administered with Fostamatinib in Healthy Subjects
